Latest Pharma and Biotech News
Pharmaceutical
2 December 2024 GLP-1 receptor (GLP-1R) products have gained immense popularity in recent years, and four are currently approved in major markets to treat obesity—all of which are injectables.
Today's issue
Refine Search
Pharmaceutical
Japanese pharma major Takeda has agreed an exclusive licensing agreement with US pharma Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. 3 December 2024
Pharmaceutical
US privately-held biotech COUR Pharmaceuticals has entered into a strategic collaboration and licensing agreement with Roche subsidiary Genentech for the development and commercialization of COUR’s proprietary tolerogenic nanoparticle treatments for an autoimmune disease. 3 December 2024
Biotechnology
US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target. 3 December 2024
Pharmaceutical
Suzhou’s Atom Therapeutics, has inked a deal with China Medical System (CMS) to commercialize lingdolinurad (ABP-671) in China, Hong Kong, and Macao. 3 December 2024
Biotechnology
California’s XOMA Royalty Corporation has announced that it now owns an economic interest in seralutinib, a Phase III asset being studied in pulmonary arterial hypertension (PAH), through its $20 million acquisition of Pulmokine, a privately-held company. 3 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant Novartis in frontline metastatic breast cancer. 3 December 2024
Biotechnology
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies, has announced the appointment of Eckhard Niemeier as its chief business officer (CBO). 3 December 2024
Biotechnology
Licensing agreement deal value for innovative T-cell receptor (TCR) immunotherapy drugs surged in 2024, with European biopharmaceutical companies reporting a 325% surge ($921 million) from 2023 to 2024 year-to-date (YTD), compared to a 90.5% rise ($256 million) in the USA. 3 December 2024
Biotechnology
China's National Medical Products Administration (NMPA) has granted conditional approval for a combination therapy of Elunate (fruquintinib) and Tyvyt (sintilimab). 3 December 2024
Pharmaceutical
The Advanced Research Projects Agency for Health (ARPA-H), an agency established in 2022 in the USA, has launched a new Advancing Clinical Trial Readiness (ACTR) initiative. 3 December 2024
Biotechnology
Nearly seven years after its founding, Senti Biosciences has announced promising results from its Phase I trial for SENTI-202. 3 December 2024
Biotechnology
New results from the RESOLUTION trial demonstrate the efficacy of Vyepti (eptinezumab) on top of patient education for patients severely impacted by migraine. 3 December 2024
Biotechnology
French immunotherapy company OSE Immunotherapeutics announced that it has strengthened the company’s leadership and executive team with two new appointments. 3 December 2024
Pharmaceutical
Bausch Health Bausch Health (NYSE/TSX: BHC) has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. 3 December 2024
Biotechnology
French biotech Ipsen has entered an exclusive global licensing agreement with Biomunex Pharmaceuticals to develop BMX-502, a first-in-class T cell engager. 3 December 2024
Pharmaceutical
Swedish pharma Orexo and Germany-based digital therapeutics company GAIA have decided to end their partnership agreement for the former firm to commercialize the digital mental health program for depression, Deprexis, in the USA. 2 December 2024
Biotechnology
Netherlands and USA-based Merus has inked an exclusive licensing accord with privately-held Partner Therapeutics (PTx), for the right to commercialize zenocutuzumab (Zeno) for the treatment of NRG1 fusion-positive (NRG1+) cancer in the USA. 2 December 2024
Pharmaceutical
Switzerland-based Novocure saw its shares leap 38% to $27.64 as it revealed positive results from the pivotal, Phase III PANOVA-3 trial, demonstrating a statistically-significant improvement in median overall survival (mOS) versus control. 2 December 2024
Pharmaceutical
A Feature on M&A, licensing, and partnership tapping into AI’s potential to improve drug development. 2 December 2024
All news
Pharmaceutical
Japanese pharma major Takeda has agreed an exclusive licensing agreement with US pharma Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. 3 December 2024
Pharmaceutical
US privately-held biotech COUR Pharmaceuticals has entered into a strategic collaboration and licensing agreement with Roche subsidiary Genentech for the development and commercialization of COUR’s proprietary tolerogenic nanoparticle treatments for an autoimmune disease. 3 December 2024
Biotechnology
US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target. 3 December 2024
Pharmaceutical
Suzhou’s Atom Therapeutics, has inked a deal with China Medical System (CMS) to commercialize lingdolinurad (ABP-671) in China, Hong Kong, and Macao. 3 December 2024
Biotechnology
California’s XOMA Royalty Corporation has announced that it now owns an economic interest in seralutinib, a Phase III asset being studied in pulmonary arterial hypertension (PAH), through its $20 million acquisition of Pulmokine, a privately-held company. 3 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant Novartis in frontline metastatic breast cancer. 3 December 2024
Biotechnology
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies, has announced the appointment of Eckhard Niemeier as its chief business officer (CBO). 3 December 2024
Biotechnology
Licensing agreement deal value for innovative T-cell receptor (TCR) immunotherapy drugs surged in 2024, with European biopharmaceutical companies reporting a 325% surge ($921 million) from 2023 to 2024 year-to-date (YTD), compared to a 90.5% rise ($256 million) in the USA. 3 December 2024
Biotechnology
China's National Medical Products Administration (NMPA) has granted conditional approval for a combination therapy of Elunate (fruquintinib) and Tyvyt (sintilimab). 3 December 2024
Pharmaceutical
The Advanced Research Projects Agency for Health (ARPA-H), an agency established in 2022 in the USA, has launched a new Advancing Clinical Trial Readiness (ACTR) initiative. 3 December 2024
Biotechnology
Nearly seven years after its founding, Senti Biosciences has announced promising results from its Phase I trial for SENTI-202. 3 December 2024
Biotechnology
New results from the RESOLUTION trial demonstrate the efficacy of Vyepti (eptinezumab) on top of patient education for patients severely impacted by migraine. 3 December 2024
Biotechnology
French immunotherapy company OSE Immunotherapeutics announced that it has strengthened the company’s leadership and executive team with two new appointments. 3 December 2024
Pharmaceutical
Bausch Health Bausch Health (NYSE/TSX: BHC) has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. 3 December 2024
Biotechnology
French biotech Ipsen has entered an exclusive global licensing agreement with Biomunex Pharmaceuticals to develop BMX-502, a first-in-class T cell engager. 3 December 2024
Pharmaceutical
Swedish pharma Orexo and Germany-based digital therapeutics company GAIA have decided to end their partnership agreement for the former firm to commercialize the digital mental health program for depression, Deprexis, in the USA. 2 December 2024
Biotechnology
Netherlands and USA-based Merus has inked an exclusive licensing accord with privately-held Partner Therapeutics (PTx), for the right to commercialize zenocutuzumab (Zeno) for the treatment of NRG1 fusion-positive (NRG1+) cancer in the USA. 2 December 2024
Pharmaceutical
Switzerland-based Novocure saw its shares leap 38% to $27.64 as it revealed positive results from the pivotal, Phase III PANOVA-3 trial, demonstrating a statistically-significant improvement in median overall survival (mOS) versus control. 2 December 2024
Pharmaceutical
A Feature on M&A, licensing, and partnership tapping into AI’s potential to improve drug development. 2 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze